Introduction and Aim:
A yearly oral glucose tolerance test (OGTT) is advised to diagnose CF-related diabetes (CFRD), from the age of 10 yrs and up. This test does not reflect a real-life situation, is disliked by patients and not fully adhered to. The aim of this study is to test the acceptance and results of a real-life glucose tolerance test (RLGTT) and compare positive outcomes with the OGTT, from Jan 2010 to Dec 2011. Materials and Methods: For the yearly check up 33 children with CF of 10−17 yrs, not already diagnosed with CFRD, were admitted. The carbohydrates of the meal are registered according to the Dutch Food Composition Table 2006 . The RLGTT consists of a 4 hour fasting period followed by eating a minimum of 1.25 g carbohydrates per kg bodyweight in a regular meal, with a maximum of 1.75 g/kg or 75 g carbohydrates. A glucose sample is taken before and 2 hours after the meal. A 2 hour glucose of >9 mmol/L after 1.50-1.75 g/kg or >8 mmol/L after 1.25-1.50 g/kg is considered abnormal. Stricter cut-off values in comparison to OGTT were set, because of the use of a meal instead of glucose. Results: We did 47 tests in 33 patients. All patients easily accepted the test in this design. An impaired fasting glycemia was found 2 times. In 7/47 tests (7/33 patients) results were abnormal with a mean postprandial glucose of 11.0 mmol/L (8.2 to 11.1 mmol/L). In 6 patients an OGTT pointed out CFRD. They all started with insulin once a day. Conclusion: The RLGTT is a good predictor of CFRD, is easily accepted and implemented in regular care. An abnormal RLGTT should be followed by intensive monitoring of blood glucose.
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M. Falco 1 , F. De Gregorio 1 , V. Fattorusso 1 , V. Mozzillo 1 , A. Casale 1 , S. De Santis 1 , N. Amato 1 , C. Tortora 1 , A. Franzese 1 , V. Raia 1 , A. Tosco 1 . 1 University of Naples 'Federico II', Pediatrics, Naples, Italy Objectives: CF-related diabetes (CFRD) is related to worsening pulmonary function and increased mortality and its prevalence is significantly high beyond the first decade of life. Current guidelines recommend annual OGTT as screening method of CFRD for all CF patients 10 years. We evaluated glucose abnormalities among patients 10 years regularly attending the CF Regional Centre of Naples. Methods: From 2004 to 2010 67 patients 10 years (30 F) without CFRD were screened for glucose abnormalities by fasting 2 h-1.75g/kg OGTT and classified as NGT, IGT, INDET, CFRD according to current guidelines [1] . The inclusion criteria were: pancreatic insufficiency, no acute pulmonary exacerbation and no current steroid therapy. Mean age at the time of OGTT was 80.4 months (range 30-118), median age 83 months. We identified 18 NGT (26.8%), 4 INDET (6%), 11 IGT (16.4%), 4 CFRD (6%). 30 patients (44.7%) resulted with glucose levels 140 mg/dl in the middle of OGTT. Conclusions: More CF patients 10 years had glucose abnormalities than previous reports. Our data suggest that also patients 10 years, have to be early screened for CFRD. Larger prospective studies need to define the prognostic role of INDET and IGT status, as well as to assess the prognostic role of abnormal glucose tolerance (AGT − glucose level 140 mg/dl in the middle of OGTT) in CF patients. . This is time consuming, inconvenient and disliked by some patients. We have previously shown that using a combination of HbA1c, random glucose (RBG), annual FEV 1 decline and annual weight loss to screen for CFRD may be an effective alternative approach. To validate this in the wider CF population we performed the current study to determine the most accurate criteria for predicting patients with a positive OGTT requiring treatment.
Method: Prospective study of consecutive adult CF patients (not known to have CFRD) attending an annual review assessment between March 2009 and December 2011. All patients had an OGTT. In parallel they had: HbA1c, RBG, and calculation of annual %predicted FEV 1 and weight decline. Results: Data for 323 patients (mean±SD age = 31±10, 42% female, 76% pancreatic insufficient) were collected. Mean±SD RBG = 5.40±1.6; HbA1c = 5.4±0.6; annual %predicted FEV1 change −0.6%±2.7; annual %weight change +1%±3. OGTT at 120 min 7.8-11.0 mmol/l, n = 43; at 120 min >11, n = 17. By systematic approach the optimal criteria for predicting a positive OGTT was: HbA1c 5.8% (n = 171) and/or RBG >11 mmol/l (n = 6). This provided a test accuracy of 94.1% sensitivity and 49.3% specificity. The one patient missed by these criteria is clinically well and not currently requiring insulin. Conclusion: This large study confirms the validity of performing an OGTT selectively. The use of two biochemical markers − HbA1c 5.8% and RBG >11 mmol/l − provides an excellent test accuracy for CFRD screening, reducing the need for an OGTT by nearly 50%.
